Figure 1
From: FGFR1 is amplified during the progression of in situto invasive breast carcinoma
Analysis of HER2 , C-MYC , CCND1 and FGFR1 amplification by fluorescence in situ hybridization. (A) Representative examples of HER2, C-MYC, CCND1 and FGFR1 amplification in pure ductal carcinoma in situ (DCIS). (B) Comparison of gene amplification status in the invasive and DCIS component of the same tumors. CCND1 is amplified in both the invasive and DCIS components of a tumor. However, FGFR1 is amplified in the invasive component but not in the DCIS component of a tumor. HER2, C-MYC, CCND1 and FGFR1-specific probes are red, and centromeric probes (chromosome 17 for HER2, chromosome 8 for C-MYC and FGFR1, and chromosome 11 for CCND1) are green. Scale bar: 25 μm. Magnification: ×400 (H & E) and ×1,000 (fluorescence in situ hybridization).